Related Experiment Video

Updated: Oct 2, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The effects of platelet inhibitors on blood use in cardiac surgery

Leonard Y Lee1, William DeBois, Karl H Krieger

  • 1New York Presbyterian Hospital, Weill Cornell Center, New York 10021, USA.

Perfusion
|January 31, 2002
PubMed

Insights

Glycoprotein IIb/IIIa inhibitors reduce emergent cardiac surgery but increase bleeding risk. Careful planning allows safe coronary artery bypass surgery (CABG) for patients on these antiplatelet agents.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Pharmacology

Background:

  • Glycoprotein (GP) IIb/IIIa receptor antagonists have decreased emergent cardiac surgery rates.
  • These agents increase bleeding risk for patients undergoing cardiac surgery.
  • Managing patients on GP IIb/IIIa inhibitors presents challenges for surgical teams.

Purpose of the Study:

  • To review current guidelines for managing patients on GP IIb/IIIa inhibitors requiring coronary artery bypass surgery (CABG).
  • To discuss the risks and benefits associated with GP IIb/IIIa inhibitor use in cardiac surgery.
  • To emphasize the possibility of safely performing urgent CABG in these patients with proper planning.

Main Methods:

  • Review of current clinical guidelines for managing patients on GP IIb/IIIa inhibitors.
  • Discussion of perioperative management strategies including drug cessation, surgical delay, ultrafiltration, heparin dosing, and platelet transfusion.
  • Analysis of the impact of GP IIb/IIIa inhibitors on bleeding risk and surgical outcomes.

Main Results:

  • Guidelines recommend cessation of GP IIb/IIIa inhibitors and a potential delay of surgery.
  • Strategies like ultrafiltration and standard heparin dosing are employed.
  • Platelet transfusion is used as needed, not prophylactically.

Conclusions:

  • GP IIb/IIIa inhibitors increase bleeding risk during CABG but offer significant benefits in acute coronary syndromes.
  • Judicious planning and adherence to current guidelines enable safe performance of urgent coronary artery bypass surgery.
  • The overall risk-benefit profile favors the use of these agents in appropriate patient populations.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...